Provided by Tiger Trade Technology Pte. Ltd.

Global X Aging Population ETF

39.10
+0.27440.71%
Post-market: 39.100.00000.00%16:10 EDT
Volume:2K
Turnover:85.52K
Market Cap:96.57M
PE:- -
High:39.10
Open:38.94
Low:38.82
Close:38.83
52wk High:39.48
52wk Low:32.44
Shares:2.47M
Float Shares:2.47M
Volume Ratio:0.20
T/O Rate:0.09%
Dividend:0.33
Dividend Rate:0.83%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?

Simply Wall St.
·
Yesterday

Eli Lilly (LLY) On Foundayo Launch And Higher Outlook Faces A Rich Valuation

Simply Wall St.
·
Aug 24

Welltower Declares Q3 2026 Distribution of R$ 1.48 Per Unit, Payable Aug. 26

Reuters
·
Aug 24

Roche, Eli Lilly's Alzheimer's Blood Test Gets FDA Clearance

Reuters
·
Aug 24

ANI Pharma Appoints Henry Gosebruch to Board of Directors

Reuters
·
Aug 24

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 24

Eli Lilly: Working with Nice on Assessment of Foundayo for Potential Use on Nhs in England

THOMSON REUTERS
·
Aug 24

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Reuters
·
Aug 24

Eli Lilly: Foundayo NOW Available in UK to be Prescribed for Eligible Adults Via Private Prescription

THOMSON REUTERS
·
Aug 24

Eli Lilly: in UK, Foundayo is Priced Lower than Mounjaro; Likely to be in Order of £100 to £120

THOMSON REUTERS
·
Aug 24

Johnson & Johnson, AbbVie, Chevron, Energy Transfer, Home Depot Shaken

TIPRANKS
·
Aug 22

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 22

AbbVie Expands Aesthetics Pipeline With New Phase 2 Forehead Lines Study

TIPRANKS
·
Aug 22

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Aug 22

AbbVie Targets Pediatric Alopecia With New Phase 3 Trial: What Investors Should Watch

TIPRANKS
·
Aug 22

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Aug 22

AbbVie’s Emraclidine Schizophrenia Study Ends Early: What Investors Need to Know Now

TIPRANKS
·
Aug 22

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims

TIPRANKS
·
Aug 21

Ventas (VTR) Gets a Hold from UBS

TIPRANKS
·
Aug 21